Phase III data on Quince Therapeutics’ EryDex
US rare diseases focused company Quince Therapeutics (Nasdaq: QNCX) today announced the online publication of data in The Lancet Neurology from its Phase III ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem clinical trial evaluating the safety and efficacy of its lead asset, EryDex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes), for the treatment of ataxia-telangiectasia (A-T), an inherited neurodegenerative and immunodeficiency disorder.
Quince gained rights to EryDex along with its acquisition last year of Italy-based EryDel, in a deal worth up to $485 million. There are currently no approved therapeutic treatments in any global market for this rare pediatric disease.
Highlights of the Phase III trial include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze